Rivaroxaban in acute venous thromboembolism: UK prescribing experience.

ABSTRACT:

Background

Rivaroxaban was reported as effective as traditional therapies for the acute treatment of venous thromboembolism (VTE) with fewer major bleeding complications in the seminal Einstein program and is now a recommended option for the treatment of VTE around the world.

Objective

To report the safety and efficacy of rivaroxaban in daily care for the management of acute VTE in the United Kingdom.

Patients/method

The FIRST registry is a UK-only, multicenter, noninterventional, observational VTE study (NCT02248610). Consecutive patients diagnosed with acute VTE, managed with rivaroxaban, were recruited and followed for up to 5 years. The primary outcomes were treatment-emergent symptomatic objectively diagnosed recurrent VTE, major and clinically relevant nonmajor

SUBMITTER: Speed V 

PROVIDER: S-EPMC8531140 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature